

The **only** sublingual grass allergy immunotherapy tablet with a mixed pollens allergen extract from 5 grasses¹

Oralair[®]

(Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract)
Tablet For Sublingual Use

- An important immunotherapy option for patients with grass allergies
- Effective during the first pollen season
- Demonstrated safety profile

Visit [ORALAIR.com](https://www.oralair.com) to learn more.

Initiate treatment with ORALAIR[®] 4 months before the expected onset of each grass pollen season and maintain it throughout the grass pollen season.¹

Indications and Usage

ORALAIR[®] is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or *in vitro* testing for pollen-specific IgE antibodies for any of the 5 grass species contained in this product. ORALAIR is approved for use in persons 10 through 65 years of age.

ORALAIR is not indicated for the immediate relief of allergy symptoms.

Important Safety Information

WARNING: SEVERE ALLERGIC REACTIONS

- **ORALAIR can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal edema.**
- **Do not administer ORALAIR to patients with severe, unstable or uncontrolled asthma.**
- **Observe patients in the office for at least 30 minutes following the initial dose.**
- **Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.**
- **ORALAIR may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.**
- **ORALAIR may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.**

Please see additional Important Safety Information on last page. Please see full Prescribing Information, including Boxed Warning and Medication Guide, at [ORALAIR.com](https://www.oralair.com).



Important Safety Information

WARNING: SEVERE ALLERGIC REACTIONS

- **ORALAIR® can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal edema.**
- **Do not administer ORALAIR to patients with severe, unstable or uncontrolled asthma.**
- **Observe patients in the office for at least 30 minutes following the initial dose.**
- **Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.**
- **ORALAIR may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.**
- **ORALAIR may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.**

ORALAIR is contraindicated in patients with severe, unstable or uncontrolled asthma, patients with a history of any severe systemic allergic reaction or severe local reaction to sublingual allergen immunotherapy or of eosinophilic esophagitis, or patients who are hypersensitive to any of the inactive ingredients.

ORALAIR can cause systemic allergic reactions, including anaphylaxis, and severe local reactions, including laryngopharyngeal swelling, which may be life-threatening. Severe and serious allergic reactions may require treatment with epinephrine. Patients who have a systemic allergic reaction to ORALAIR should stop taking the product. Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy. Discontinue ORALAIR in patients with persistent symptoms of eosinophilic esophagitis, including dysphagia or chest pain. ORALAIR treatment should be withheld if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ORALAIR. Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.

In case of oral inflammation or wounds, such as following oral surgery or dental extraction, ORALAIR treatment should be discontinued to allow complete healing of the oral cavity. The risk of ORALAIR may be increased when treatment is initiated during the grass pollen season.

The most common adverse events reported in $\geq 5\%$ of patients were oral pruritus, throat irritation, ear pruritus, mouth edema, tongue pruritus, cough, and oropharyngeal pain. Patients who have escalating or persistent local reactions to ORALAIR should be reevaluated and considered for discontinuation of ORALAIR.

ORALAIR should be used during pregnancy or breastfeeding only if clearly needed.

Please see accompanying full Prescribing Information, including Boxed Warning and Medication Guide.

Reference: 1. ORALAIR full Prescribing Information, Stallergenes SAS 2014.

Oralair®(Sweet Vernal, Orchard, Perennial Rye,
Timothy, and Kentucky Blue Grass
Mixed Pollens Allergen Extract)

Tablet For Sublingual Use

This form is only to be used when faxing directly to a specialty
pharmacy within the ORALAIR® network of pharmacies.**Patient Information** (to be used by Specialty Pharmacy)

Patient Name: _____

Address: _____

City, State, Zip: _____

Primary Phone: _____ Alternate Phone: _____

Date of Birth: _____ Gender: _____

Medication Allergies: _____

E-mail: _____

Last 4 Digits of Social Security Number: _____

Parent/Guardian: _____

Prescriber Information (To be used as a prescription, prescriber must
fully complete the prescription information section on this form.)

Prescriber's First Name: _____

Prescriber's Last Name: _____

State License Number: _____

NPI Number: _____ DEA Number: _____

Address: _____

City, State, Zip: _____

Phone: _____ Fax: _____

Contact Person: _____

Contact Phone: _____

Delivery/Shipping OptionsShip to Patient's Home ☐ Other ☐ _____**Insurance Information****Prescription Card (Drug Insurance)**

Name of Insurer: _____

ID Number: _____

BIN: _____

PCN: _____

Group: _____

**Please copy the front and back of insurance card and ORALAIR
co-pay card (if patient has one), and attach all pages to this form.****Diagnosis and Clinical Information**☐ J30.1 Allergic Rhinitis due to Pollen☐ Other: _____

Date of Diagnosis: _____

Prescription Information (This form can also be used to prescribe auto-injectable epinephrine.)

MEDICATION	DOSE/STRENGTH	DIRECTIONS	QUANTITY	REFILLS

Prescriber Signature Required

Dispense as written _____ Date: _____

Substitution allowed _____

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee. **Please see Important Safety Information on last page. Please see full Prescribing Information, including Boxed Warning and Medication Guide, at ORALAIR.com.**

Indications and Usage

ORALAIR® is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or *in vitro* testing for pollen-specific IgE antibodies for any of the 5 grass species contained in this product. ORALAIR is approved for use in persons 10 through 65 years of age.

ORALAIR is not indicated for the immediate relief of allergy symptoms.

Important Safety Information

WARNING: SEVERE ALLERGIC REACTIONS

- **ORALAIR can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal edema.**
- **Do not administer ORALAIR to patients with severe, unstable or uncontrolled asthma.**
- **Observe patients in the office for at least 30 minutes following the initial dose.**
- **Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.**
- **ORALAIR may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.**
- **ORALAIR may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.**

ORALAIR is contraindicated in patients with severe, unstable or uncontrolled asthma, patients with a history of any severe systemic allergic reaction or severe local reaction to sublingual allergen immunotherapy or of eosinophilic esophagitis, or patients who are hypersensitive to any of the inactive ingredients.

ORALAIR can cause systemic allergic reactions, including anaphylaxis, and severe local reactions, including laryngopharyngeal swelling, which may be life-threatening. Severe and serious allergic reactions may require treatment with epinephrine. Patients who have a systemic allergic reaction to ORALAIR should stop taking the product. Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy. Discontinue ORALAIR in patients with persistent symptoms of eosinophilic esophagitis, including dysphagia or chest pain. ORALAIR treatment should be withheld if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ORALAIR. Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.

In case of oral inflammation or wounds, such as following oral surgery or dental extraction, ORALAIR treatment should be discontinued to allow complete healing of the oral cavity. The risk of ORALAIR may be increased when treatment is initiated during the grass pollen season.

The most common adverse events reported in ≥5% of patients were oral pruritus, throat irritation, ear pruritus, mouth edema, tongue pruritus, cough, and oropharyngeal pain. Patients who have escalating or persistent local reactions to ORALAIR should be reevaluated and considered for discontinuation of ORALAIR.

ORALAIR should be used during pregnancy or breastfeeding only if clearly needed.

Please see accompanying full Prescribing Information, including Boxed Warning and Medication Guide.

Reference: 1. ORALAIR full Prescribing Information, Stallergenes SAS 2014.

ORALAIR® is a registered trademark of Stallergenes Greer or its affiliates.

Stallergenes Greer PO Box 800, 639 Nuway Circle NE, Lenoir, NC 28645 1.844.672.5247
© Stallergenes Greer 2016. All Rights Reserved. MPN 072816H1929 08.16 5K

Participating specialty pharmacy list:

Acro Specialty Pharmacy:

- Fax referral to: 877-381-3806
- Phone: 800-906-7798

National Specialty Pharmacy

- ✓ MOST COMMERCIAL PAYORS
ACCEPTED

AllCarePlus Pharmacy:

- Fax referral to: 508-459-3534
- Phone: 855-880-1091

National Specialty Pharmacy

- ✓ MOST COMMERCIAL PAYORS
ACCEPTED

CVS Caremark Specialty Pharmacy:

- Fax referral to: 800-323-2445
- Phone: 800-237-2767

National Specialty Pharmacy

- ✓ MOST COMMERCIAL PAYORS
ACCEPTED
- ✓ MOST MEDICAID PAYORS
ACCEPTED

Optum Rx Specialty Pharmacy:

- Fax referral to: 800-853-3844
- Phone: 866-218-5445

National Specialty Pharmacy

- ✓ ONLY United Healthcare
Patients Accepted

Prime Therapeutics

Specialty Pharmacy:

- Fax referral to: 877-828-3939
- Phone: 877-627-6337

National Specialty Pharmacy

- ✓ LIMITED PAYORS ACCEPTED
— SELECT BLUE CROSS BLUE
SHIELD AFFILIATES IN THE
FOLLOWING STATES:

AL	MS	NM
AR	MT	OK
FL	NC	SC
IL	ND	TX
KS	NE	WY
MN	NJ	

Publix Specialty Pharmacy:

- Fax referral to: 863-413-5723
- Phone: 855-797-8254

Regional Specialty Pharmacy

- ✓ MOST COMMERCIAL PAYORS
ACCEPTED
- FL, GA, AL, TN
- NC, SC (in-store pickup only)

Walgreens/Duane Reade Specialty Pharmacy:

- Fax referral to: 877-231-8302
- Phone: 888-347-3416

National Specialty Pharmacy

- ✓ MOST COMMERCIAL PAYORS
ACCEPTED
- ✓ MOST MEDICAID PAYORS
ACCEPTED

Important Safety Information

WARNING: SEVERE ALLERGIC REACTIONS

- ORALAIR can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal edema.
- Do not administer ORALAIR to patients with severe, unstable or uncontrolled asthma.
- Observe patients in the office for at least 30 minutes following the initial dose.
- Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.
- ORALAIR may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.
- ORALAIR may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

Please see Indications and Usage and additional Important Safety Information on reverse side. Please see accompanying full Prescribing Information, including Boxed Warning and Medication Guide.